Lyra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
16/08/2024 13:00
* Lyra Therapeutics Inc LYRA.OQ reported a quarterly
adjusted
loss of 74 cents per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -32 cents. The mean expectation of five analysts for the
quarter was for a loss of 33 cents per share. Wall Street
expected results to range from -36 cents to -27 cents per share.
* Revenue rose 30.6% to $598.00 thousand from a year ago;
analysts
expected $349.80 thousand.
* Lyra Therapeutics Inc's reported EPS for the quarter was a
loss
of 74 cents.
* The company reported a quarterly loss of $48.13 million.
* Lyra Therapeutics Inc shares had risen by 4.8% this
quarter and
lost 94.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for Lyra Therapeutics
Inc is $1.25
This summary was machine generated from LSEG data August 16 at
12:00 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.33 -0.74 Missed
Mar. 31 2024 -0.26 -0.35 Missed
Dec. 31 2023 -0.31 -0.22 Beat
Sep. 30 2023 -0.32 -0.27 Beat